Next-generation dual-agonist — studied as more potent than single GLP-1 in preclinical models. 100+ published references. 99%+ HPLC-verified purity. 3-lab independent COA on every batch.
GLP-2TZ is a dual GIP/GLP-1 receptor agonist — a next-generation incretin-pathway compound that simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism distinguishes it from single-target GLP-1 agonists like glp-1sm.
With 100+ published references in the preclinical and clinical literature, glp-2tz is one of the most actively studied metabolic peptides. Researchers examine its role in dual incretin pathway activation, glucose-dependent insulin signaling, appetite regulation, and broader metabolic pathway modulation.
GLP-2TZ is classified as a research-use-only compound at SMART MD Peptides. All references below describe research contexts. Not FDA-approved for any therapeutic indication when sold as a research compound.
Studied for simultaneous GIP and GLP-1 receptor engagement. Preclinical models suggest dual agonism may produce synergistic metabolic effects beyond what either pathway achieves independently.
Research examines glp-2tz's effects on insulin secretion that activates proportionally to glucose levels — a key safety feature studied in metabolic models to understand glycemic regulation.
Published studies explore glp-2tz's role in central appetite signaling pathways, including hypothalamic satiety center modulation and delayed gastric emptying mechanisms in preclinical models.
Emerging research examines broader metabolic effects including lipid metabolism, adipose tissue signaling, and hepatic glucose output — areas where dual agonism may offer advantages over single-pathway compounds.
GLP-2TZ is a dual GIP/GLP-1 receptor agonist — a next-generation incretin peptide that simultaneously activates both GIP and GLP-1 receptors. This dual mechanism has been studied as more potent than single GLP-1 agonists in preclinical metabolic models. SMART MD offers research-grade glp-2tz in 10mg, 30mg, and 60mg formulations.
GLP-1SM is a single GLP-1 receptor agonist. GLP-2TZ is a dual agonist targeting both GIP and GLP-1 receptors simultaneously. Preclinical and clinical research suggests the dual pathway may produce enhanced metabolic effects compared to GLP-1 agonism alone. SMART MD carries both for researchers studying incretin pathway differences.
Research-grade GLP-2TZ with 3-lab COA verification is available at SMART MD Peptides in 10mg, 30mg, and 60mg formulations. Every batch is independently verified for purity (99%+) and publicly verifiable at smartmdpeptides.com/verify.
GLP-2TZ is available for research purposes. When sold as a research compound, it is classified as research-use-only — not intended for human consumption. Licensed researchers and physicians may acquire it for research protocols. SMART MD provides compliance documentation with every order.
Lyophilized (unreconstituted) GLP-2TZ should be stored at -20°C, protected from light. Once reconstituted, store at 2-8°C and use within the timeframe specified on your lot-specific documentation.
Check the COA before you buy. Compare it against any other supplier's documentation.